Debating on the Clinical Utility of Blood-Based Biomarkers for Alzheimer Diagnosis: Fanny Elahi, MD, PhD

The associate professor of neurology at Icahn School of Medicine at Mount Sinai discussed the clinical and scientific advantages of blood-based biomarkers over imaging for Alzheimer disease. [WATCH TIME: 5 minutes]:

Source: Neurology Read More

Previous PostNicotinamide Riboside Shows Effects on Hippocampal Features but Not Improved Memory
Next PostEMA Issues Negative Opinion for Sarepta’s Gene Therapy Elevidys

Debating on the Clinical Utility of Blood-Based Biomarkers for Alzheimer Diagnosis: Fanny Elahi, MD, PhD

Previous PostNicotinamide Riboside Shows Effects on Hippocampal Features but Not Improved Memory

Next PostEMA Issues Negative Opinion for Sarepta’s Gene Therapy Elevidys

Related Posts

<![CDATA[How Early Environmental Detection Could Refine Parkinson Disease Risk Models: Rodolfo Savica, MD, PhD]]>

<![CDATA[TEMPO-4 Extension Analysis: Tavapadon Shows Levodopa-Sparing Potential in Parkinson Disease]]>

<![CDATA[Telitacicept Moves Forward in Global Phase 3 Study for Generalized Myasthenia Gravis]]>

Categories